Forma Therapeutics, Inc.

Ariad Pharmaceuticals, Inc.

Nimbus Wadjet, Inc.

Takeda Pharmaceutical Company Limited

Nimbus Clio, Inc.

Nimbus Clotho, Inc.

Angela V West

Steven Gregory Mischke

Hongbin Li

Anna M Ericsson

Shawn E R Schiller

Torsten Herbertz

Bradford Graves

Jennifer R Downing

Justin Andrew Caravella

William C Shakespeare

Xiaotian Zhu

David C Dalgarno

Wei-Sheng Huang

Silvana Marcel Leit De Moradei

Feng Li

Anna Kohlmann

Nicholas E Bencivenga

Ranny M Thomas

Willmen Youngsaye

Yongjin Gong

Matthew W Martin

Robert L Dow

David James Richard

Derun Li

Yun Zhang

Tianjun Zhou

Alex J Buckmelter

Nikolay Sitnikov

Nathan E Genung

Florian Bartels

Jeremy Robert Greenwood

Kevin Douglas Kreutter

Neelu Kaila

Shaughnessy Robinson

Alexey V Ishchenko

Steven K Albanese

Lewis Whitehead

Andreas Verras

Salma Rafi

Diana Castagna

Yan Zhang

Sebastien Campos

Kevin Demarco

Fiona Mcrobb

Jokin Carrillo Arregui

Thomas Baker

Shawn ER Schiller

Yongjin Xu

The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

WRN inhibitors

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

The present disclosure is directed to compounds of Formula II-e: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CPTS1, and the treatment of CPTS1-mediated disorders.

CTPS1 inhibitors and uses thereof

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of Cbl-b, and the treatment of Cbl-b-mediated disorders.

CBL-B modulators and uses thereof

Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

Heteroaryl compounds for kinase inhibition

The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors

Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) 

Growing community of inventors

Franklin, MA, United States of America

Angela V West